Abstract:
Abstract
Background: Abnormal platelet activation and an increased risk of thrombosis are frequent findings in cancer.
Objectives: The aim of this study was to determine the heterogeneous defects of platelet count and responses to agonists among the
major Sudanese hematological malignancies patients.
Materials and Method: This study was done in Radiation & Isotopes Center Khartoum (RICK) during the period of February 2009
to October 2013. Two hundred and two (202) hospitalized and out patients who were diagnosed of having hematological malignancies
in different age groups on treatment or off treatment against fifty (50) apparently healthy (male and female) as a control group.
platelet count, platelet aggregation and D-Dimer test were done for both study groups and control.
Result: The results indicated that, significantly low platelet counts in AML, CLL (P < 0.05), and increased in CML (P < 0.05) and CGL
(P < 0.05) in related to control group, and the Study of platelet aggregation in response to ADP, Collagen, and Epinephrine agonists
was decreased in ALL, AML and MM, and in variable in CML and NHL and increased in CLL and HL. The positive D-Dimer was seen in
161 (79.7%) while 41 (20.3%) patients had negative D- Dimer results.
Conclusion: Markers of platelet defect were clearly observed in hematological malignancies patients, also indication of coagulation
activation were confirmed. Some alterations in hemostasis and thrombotic events have frequently been observed in hematological
malignancies patients. These hemostatic changes may contribute to a thrombotic and bleeding tendency in these patients.
Keywords: Cancer; Hematological Malignancies; Coagulation; Platelets Aggregation
